BioPlus (NASDAQ:BIOS) announced this morning that it has mutually terminated its combination with medical device company Avertix.
Unlike with many terminations seen recently, this parting of ways does not appear to have come directly as a result of discouraging redemption results ahead of a major vote and the two sides are still well away from their December 31 outside date.
But, Avertix said in the press release that the two sides “agreed that the current market conditions are not conducive to completing the transaction on terms acceptable to both BIOS and Avertix stakeholders”.
At issue could have been the difficult terms for securing additional outside capital. BioPlus planned to pull together a $50 million PIPE at announcement and was beholden to a $40 million minimum cash condition. The two sides had not made any financing announcements since and in the current risk-off environment, many of the options available require concessions from either sponsor or target.
BioPlus CEO Ross Haghighat has insight into both sides interest as he also already has been serving as Avertix’s executive chairman and will continue on there despite the termination. It is the end of the road for BioPlus, however.
The SPAC noted that it will not seek an alternative business combination and will liquidate as soon as practicable beginning October 4 with a redemption rate of $10.79 after dissolution expenses.
Though unfortunate, the moves come alongside a bright spot of news among biotech de-SPACs as POINT Biopharma (NASDAQ:PNT) just announced it has agreed to be acquired at $12.50 per share by peer Eli Lilly (NYSE:LLY).
At the SPAC of Dawn Pioneering an entirely new type of aircraft is necessarily a process fraught with turbulence, but eVTOL makers got a major lift Tuesday as the Federal Aviation Administration published its final ruling on “powered-lift” vehicles. This rule brings much needed clarity to the agency’s requirements for pilot training and operations and...
Horizon Space II (NASDAQ:HPSTU) has filed for a $60 million IPO to be the latest entry in the smaller tier of SPACs and underwriters to put a fresh try in motion. Since August 1, nine of the 17 new SPAC S-1’s have sought less than $200 million in their IPOs and smaller institutions like BTIG...
Flag Ship (NASDAQ:FSHP) has entered into a definitive agreement to combine with optoelectronics firm Great Rich Technologies (KOSDAQ:900290) for undisclosed terms. Great Rich manufacturers polypropylene products for consumer electronics including precision films and coatings for sensitive instruments. The combined company is expected to list American Depositary Shares (ADSs), which will trade on the Nasdaq once...
At the SPAC of Dawn With one new entry in each of the SPAC deal, IPO and new S-1 filing columns, there are revived hopes that the market will regain the pace it had set in August and September. Aldel Financial II Inc.‘s (NASDAQ:ALDFU) IPO slated for today is October’s fourth after September turned out...
Aldel Financial II Inc. announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ALDFU”, Tuesday, October 22, 2024. The new SPAC plans to combine with an established business of scale with prospects for positive cash flow and the infrastructure to handle being...